FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer By Ogkologos - September 9, 2026 84 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study 1 of the VIKTORIA-1 Source RELATED ARTICLESMORE FROM AUTHOR Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes MOST POPULAR New on NCI’s Websites for September 2021 September 1, 2021 How Your Oncology Nurse Can Help You During Cancer February 22, 2023 Berry Recipes August 14, 2020 EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab February 26, 2021 Load more HOT NEWS Doctors Think Woman Has A Brain Tumor, But Then They Open... Opinion: The Government should not be choosing between investing in staff... Detecting multiple cancers with a ‘simple’ blood test: Where are we? Man Walks Entire Continent To Spread Awareness About Mental Health &...
